0 255

Cited 10 times in

Urologic cancers in Korea

DC Field Value Language
dc.contributor.author구교철-
dc.contributor.author이광석-
dc.contributor.author정병하-
dc.date.accessioned2018-03-26T16:53:35Z-
dc.date.available2018-03-26T16:53:35Z-
dc.date.issued2015-
dc.identifier.issn0368-2811-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/156927-
dc.description.abstractThe incidence and prevalence of prostate and kidney cancers have been increasing in Korea during the last decade, and a marked improvement in survival rates has been noted. With a substantial proportion of the cancers diagnosed at an earlier stage of the disease, the landscape of urologic cancer treatment in Korea has been characterized by an exponential increase in the number of patients receiving surgical treatment. Throughout the last decade, an increasing proportion of surgeries have been performed using minimally invasive methods, with a notable increase in robot-assisted surgery. The evaluation and management strategies of urologic cancer in Korea are primarily based on an existing evidence-based framework provided by international guidelines. The adoption and clinical application of novel surgical techniques and systemic agents targeted at advanced stage cancer are promptly adopted; accordingly, multidisciplinary treatment options are often available for various cancers at different stages. At the same time, treatment decisions are greatly influenced by the availability of healthcare resources, which may be limited due to the National Health Insurance reimbursement policy. A racial disparity in cancer features appears to exist for certain urologic cancers among Korean patients, and the optimal management strategy specific for the Korean population has yet to be confirmed. A national comprehensive cancer database is needed for better insight into risk factors, selection of sequential strategies, tumor biology and survival outcome of Korean urologic cancer patients.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherOxford University Press-
dc.relation.isPartOfJAPANESE JOURNAL OF CLINICAL ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHHumans-
dc.subject.MESHKidney Neoplasms/epidemiology*-
dc.subject.MESHKidney Neoplasms/mortality-
dc.subject.MESHKidney Neoplasms/pathology-
dc.subject.MESHMale-
dc.subject.MESHNeoplasm Metastasis-
dc.subject.MESHPrevalence-
dc.subject.MESHProstatic Neoplasms/epidemiology*-
dc.subject.MESHProstatic Neoplasms/mortality-
dc.subject.MESHProstatic Neoplasms/pathology-
dc.subject.MESHRepublic of Korea/epidemiology-
dc.subject.MESHSurvival Rate-
dc.subject.MESHUrinary Bladder Neoplasms/epidemiology*-
dc.subject.MESHUrinary Bladder Neoplasms/mortality-
dc.subject.MESHUrinary Bladder Neoplasms/pathology-
dc.titleUrologic cancers in Korea-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Urology-
dc.contributor.googleauthorKyo Chul Koo-
dc.contributor.googleauthorKwang Suk Lee-
dc.contributor.googleauthorByung Ha Chung-
dc.identifier.doi10.1093/jjco/hyv096-
dc.contributor.localIdA00188-
dc.contributor.localIdA02668-
dc.contributor.localIdA03607-
dc.relation.journalcodeJ01207-
dc.identifier.eissn1465-3621-
dc.identifier.pmid26117494-
dc.subject.keywordbladder cancer-
dc.subject.keywordkidney cancer-
dc.subject.keywordprostate cancer-
dc.contributor.alternativeNameKoo, Kyo Chul-
dc.contributor.alternativeNameLee, Kwang Suk-
dc.contributor.alternativeNameChung, Byung Ha-
dc.contributor.affiliatedAuthorKoo, Kyo Chul-
dc.contributor.affiliatedAuthorLee, Kwang Suk-
dc.contributor.affiliatedAuthorChung, Byung Ha-
dc.citation.volume45-
dc.citation.number9-
dc.citation.startPage805-
dc.citation.endPage811-
dc.identifier.bibliographicCitationJAPANESE JOURNAL OF CLINICAL ONCOLOGY, Vol.45(9) : 805-811, 2015-
dc.identifier.rimsid41236-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.